FY2025 EPS Estimates for HRMY Reduced by Cantor Fitzgerald

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of $2.43 for the year, down from their prior forecast of $3.27. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

A number of other equities analysts have also recently issued reports on the stock. HC Wainwright dropped their price target on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday. Mizuho cut their price target on shares of Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating on the stock in a report on Thursday, February 20th. Needham & Company LLC reissued a “buy” rating and set a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $53.11.

Harmony Biosciences Trading Down 2.2 %

Harmony Biosciences stock opened at $32.75 on Friday. Harmony Biosciences has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The business’s fifty day simple moving average is $36.64 and its two-hundred day simple moving average is $35.79. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $201.30 million for the quarter, compared to analysts’ expectations of $201.25 million. During the same period in the previous year, the firm posted $0.45 EPS. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC grew its position in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Harmony Biosciences in the fourth quarter worth about $41,000. KBC Group NV lifted its position in shares of Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Harmony Biosciences during the 3rd quarter valued at approximately $74,000. 86.23% of the stock is currently owned by institutional investors.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is owned by company insiders.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.